Methods of monitoring adverse reactions to drugs

By Jan Venulet
Division of Clinical Pharmacology, Department of Medicine, Hôpital Cantonal and University of Geneva, Geneva, Switzerland

1 Hazards of drug therapy .................................................. 233
   1.1 Medical importance of drug adverse reactions ................. 233
   1.2 Economic aspects of drug adverse reactions .................. 234
   1.3 Present situation .................................................. 235
   1.4 Definitions .................................................................. 236
2 Building up of information on drug adverse reactions ............. 237
   2.1 Steps in recognition and action in the area .................... 237
   2.2 Requisition of drug adverse reaction data ...................... 239
   2.2.1 Medical literature ................................................. 239
   2.2.2 Systematic acquisition of information (monitoring) ........ 239
3 Drug monitoring concepts ............................................... 240
   3.1 Spontaneous drug monitoring ........................................ 240
   3.2 Intensive (comprehensive) drug monitoring .................... 241
   3.3 Monitoring of changes in population health .................... 242
   3.4 Prospective and retrospective drug monitoring ............... 243
   3.4.1 Retrospective (backward) approach ........................... 244
   3.4.2 Prospective (forward) approach .................................. 244
   3.5 Population to be monitored ......................................... 245
   3.5.1 Methodological differences between hospital and non-hospital monitoring 246
   3.6 Drug monitoring in phase 1 of clinical trials .................. 246
   3.6.1 Where animal studies have less to contribute ............... 247
   3.6.2 Factors relative to the method of work ....................... 248
   3.7 Post-marketing surveillance ......................................... 249
4 Epidemiologic considerations ........................................... 250
   4.1 Cohort method ....................................................... 250
   4.2 Case-control method ................................................ 252
   4.3 Sample size .......................................................... 252
   4.4 Bias and control ...................................................... 253
   4.5 Spontaneous drug monitoring ....................................... 254
   4.6 Tissue registries ..................................................... 255
5 National and international co-operation ................................ 256
   5.1 National drug monitoring centres ................................ 256
   5.2 International drug monitoring ...................................... 257
6 Interplay between different drug monitoring efforts .................. 258
   6.1 General comments ................................................... 258
   6.2 Problems of integration of heterogenous data ................. 258
   6.3 Guidelines for selecting a suitable approach ................... 259
7 Types of information required ......................................... 264
   7.1 What to collect ...................................................... 264
   7.11 Reporting form ..................................................... 264
   7.2 Nomenclatures and terminologies ................................ 273
   7.2.1 Drug terminology ................................................. 273
   7.2.2 Adverse reaction terminology ................................. 274